ATE265448T1 - Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung - Google Patents

Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung

Info

Publication number
ATE265448T1
ATE265448T1 AT00957317T AT00957317T ATE265448T1 AT E265448 T1 ATE265448 T1 AT E265448T1 AT 00957317 T AT00957317 T AT 00957317T AT 00957317 T AT00957317 T AT 00957317T AT E265448 T1 ATE265448 T1 AT E265448T1
Authority
AT
Austria
Prior art keywords
pyridazine
condensated
inhibiting action
substituted
angiogenesis inhibiting
Prior art date
Application number
AT00957317T
Other languages
German (de)
English (en)
Inventor
Jacques P Dumas
Holia N Hatoum-Mokdad
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Ning Su
Stephen James Boyer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE265448T1 publication Critical patent/ATE265448T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT00957317T 1999-08-10 2000-08-08 Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung ATE265448T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37132299A 1999-08-10 1999-08-10
PCT/US2000/021579 WO2001010859A1 (en) 1999-08-10 2000-08-08 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Publications (1)

Publication Number Publication Date
ATE265448T1 true ATE265448T1 (de) 2004-05-15

Family

ID=23463486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957317T ATE265448T1 (de) 1999-08-10 2000-08-08 Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung

Country Status (19)

Country Link
EP (1) EP1208096B1 (enExample)
JP (1) JP2003506447A (enExample)
KR (1) KR20020019969A (enExample)
CN (1) CN1378543A (enExample)
AR (1) AR025068A1 (enExample)
AT (1) ATE265448T1 (enExample)
AU (1) AU775237B2 (enExample)
BR (1) BR0013113A (enExample)
CA (1) CA2381621A1 (enExample)
CO (1) CO5180637A1 (enExample)
DE (1) DE60010280T2 (enExample)
ES (1) ES2219382T3 (enExample)
IL (1) IL147885A0 (enExample)
MX (1) MXPA02001324A (enExample)
NO (1) NO20020569L (enExample)
NZ (1) NZ517087A (enExample)
PE (1) PE20010494A1 (enExample)
WO (1) WO2001010859A1 (enExample)
ZA (1) ZA200200691B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GT200000158A (es) * 1999-09-28 2002-03-16 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
JP2006503796A (ja) * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CA2499738A1 (en) * 2002-09-24 2004-04-08 Novartis Ag Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
EP1562591A1 (en) * 2002-11-12 2005-08-17 Novartis AG Treatment of mesothelioma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2137177B1 (en) 2007-04-05 2014-05-07 Amgen, Inc Aurora kinase modulators and method of use
US8962027B2 (en) 2007-06-19 2015-02-24 Rynel Inc. Materials comprising water-soluble polymer particles and methods of making and using them
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
AU2009279760B2 (en) * 2008-08-04 2012-07-12 Amgen Inc. Aurora kinase modulators and methods of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
WO1996005176A1 (en) * 1994-08-09 1996-02-22 Eisai Co., Ltd. Fused pyridazine compound
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CA2366857C (en) * 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases

Also Published As

Publication number Publication date
CA2381621A1 (en) 2001-02-15
AU775237B2 (en) 2004-07-22
NZ517087A (en) 2004-05-28
IL147885A0 (en) 2002-08-14
JP2003506447A (ja) 2003-02-18
NO20020569D0 (no) 2002-02-05
DE60010280T2 (de) 2009-10-15
KR20020019969A (ko) 2002-03-13
EP1208096B1 (en) 2004-04-28
AR025068A1 (es) 2002-11-06
ES2219382T3 (es) 2004-12-01
PE20010494A1 (es) 2001-06-27
CO5180637A1 (es) 2002-07-30
MXPA02001324A (es) 2002-07-22
CN1378543A (zh) 2002-11-06
WO2001010859A1 (en) 2001-02-15
EP1208096A1 (en) 2002-05-29
NO20020569L (no) 2002-04-10
ZA200200691B (en) 2003-10-29
DE60010280D1 (de) 2004-06-03
BR0013113A (pt) 2002-04-30
AU6895400A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
DE69826841D1 (de) Phthalazines mit angiogenesis-hemmender wirkung
DE60012213D1 (de) Fünfgliedrige n-heterocyclen mit hypoglykämischer und hypolipidemischer wirkung
ATE265448T1 (de) Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung
ATE422494T1 (de) Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung
DE60039065D1 (de) Mehrkeulenantenne
NO20002822D0 (no) Termisk kretskontakt og bryter
DE60102555D1 (de) Verhinderung der map-aktivierten modulmaskeradeangriffe
ATE243885T1 (de) Schaltschutz
DE69931851D1 (de) Festkörpersportstäbe
PT1139761E (pt) Composicoes herbicidas e concentrados tensioactivos
NO20015744D0 (no) Bredspektrede antimikrobielle blandinger
DE50006919D1 (de) Femurschlitten
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
DE60025700D1 (de) Polyester formmasse
DE60003873D1 (de) Resistzusammensetzungen und Strukturierungsverfahren
DE60034754D1 (de) Resistzusammensetzung und Musterübertragungsverfahren
NO20004568L (no) Forbrenningsovn
DE60027819D1 (de) Elektromagnetischer mehrpoliger Schalter
NO20002823D0 (no) Termisk kretskontakt og bryter
DE60044930D1 (de) Resistzusammensetzung und Musterübertragungsverfahren
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
DE69914317D1 (de) Polyesterzusammensetzungen
DE60043762D1 (de) Schutzelement
DE69931468D1 (de) Elektromagnetischer schütz
DE60006734D1 (de) Unterbrecher

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties